---
document_datetime: 2025-06-25 13:36:12
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sugammadex-amomed-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sugammadex-amomed-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0652924
conversion_datetime: 2025-12-27 23:53:13.813608
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sugammadex Amomed

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                              |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------|
| Variation type IB /  | This was an application for a group of | 03/06/2025                          | 23/06/2025                                  | SmPC,                            | To extend the indication to include the treatment of |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000267132   | variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.2.a - To extend the indication to include the treatment of paediatric patients from birth up to less than 2 years of age, based on the final results of the paediatric study PN169 (MK-8616-P169). As a result, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC have been updated accordingly. The Package Leaflet has also been revised to reflect these changes. The changes follow assessment of the same changes for the reference product Bridion. In addition, the MAH took the opportunity to introduce editorial changes to the PI in CZ, DA, DE, EL,   | Labelling and PL   | paediatric patients from birth up to less than 2 years of age, based on the final results of the paediatric study PN169 (MK-8616-P169). As a result, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC have been updated accordingly. The Package Leaflet has also been revised to reflect these changes. The changes follow assessment of the same changes for the reference product Bridion. To update part I and VI of the RMP to include all paediatric patients, in line with the RMP of the reference product, and to add the table regarding 'Summary of changes to the risk management plan over time' to Annex 8 of Part VII.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | align with the PI of the reference product, to correct for abbreviations, spelling and grammar mistakes, and to align with the QRD template. C.I.11.z - To update part I and VI of the RMP to include all paediatric patients, in line with the RMP of the reference product, and to add the table regarding 'Summary of changes to the risk management plan over time' to Annex 8 of Part VII.                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IB / EMA/VR/0000254268 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (IB) - To update section 4.8 of the SmPC in order to include information on hypersensitivity reactions associated with the sugammadex-rocuronium complex. Furthermore, editorial changes to the Product Information involve the correction of obvious mistakes, typographical errors and minor editorial adjustments for the following languages: CS, DE, EL, EN, ES, ET, FI, FR, HR, IS, IT, LT, MT, NO, PL, PT, RO, SK, SL and SV. Finally, section 6 of the PL has been | 24/03/2025 | 23/06/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| and Portuguese local representatives.   |
|-----------------------------------------|